David Taylor (professor)

David Taylor FFRPS FRPharmS (born 1963) is a British professor. He is the head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners. Taylor has been lead author and editor of the Maudsley Prescribing Guidelines in Psychiatry since 1994. In 2014, Taylor was named as one of the top 100 clinical leaders in the UK National Health Service.[1]

Early life and education

Taylor was born in Leicester in 1963 and attended Loughborough Grammar School (1975-1982). He is the second of four brothers.

Taylor was guitarist in New Wave group The Thought Police, who supported Theatre of Hate on their 1981 UK tour.

A keen rugby player, Taylor played three seasons for Loughborough Grammar School first team and was later captain of Old Pauline FC 1st XV, for whom he made over 300 appearances, many alongside fellow Old Loughburian Patrick MacLarnon.

Taylor obtained a BSc in pharmacy and an MSc in clinical pharmacy from the University of Brighton. He later gained a PhD in clinical pharmacology at King’s College, London. He is a fellow of the Royal Pharmaceutical Society of Great Britain (FRPharmS),[2] a fellow of that organisation’s faculty (FFRPS) and an elected fellow of the Royal College of Physicians, Edinburgh (FRCPEdin). In 2020 he was made an honorary fellow of the Royal College of Psychiatrists in recognition of his "outstanding contribution to the profession and the cause of mental health".

Career

Taylor's first experience in psychiatry was in 1986 – a brief placement at the Towers Hospital in Leicester. He then worked in general medicine at hospitals in London and Sydney until joining the Maudsley hospital in 1993. He has been head of pharmacy since 1995 and Director of Pharmacy and Pathology at the South London and Maudsley NHS Foundation Trust since 2010.

In 2008, Taylor was awarded a chair in psychopharmacology at King’s College, London and also made honorary professor at the Institute of Psychiatry. Since 2010, Taylor has been head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners.[3]

Public works

Taylor was chairman of the UK Psychiatric Pharmacy Group (1997-1999) and the foundation president of the College of Mental Health Pharmacy, a role recognised by the award of a lifetime fellowship (FCMHP). He was a member of the government-appointed panel which brought in laws in drug driving[4] and is currently a member of the Advisory Council on the Misuse of Drugs.[5]

Taylor has been a member of several NICE panels responsible for drawing up treatment guidelines in mental health.

Since 2011 he has been editor-in-chief of Therapeutic Advances in Psychopharmacology.[6]

Taylor is widely recognised as an expert witness on the effect of drugs on behaviour and has given testimony on over two hundred civil and criminal cases.

Research work

Taylor has authored over 330 papers in peer-reviewed journals such as the Lancet, BMJ, British Journal of Psychiatry and Journal of Clinical Psychiatry, on subjects ranging from the value of long-acting antipsychotic injections, the efficacy of psilocybin as an antidepressant and the efficacy and safety of agomelatine. Taylor’s research has helped develop understanding of the use of clozapine.[7][8] Most recently he has tackled the controversial subjects of discontinuation of antidepressants[9] and antipsychotics.[10]

Maudsley Prescribing Guidelines

Taylor was the originator of the idea of an evidenced-based mental health prescribing guideline along with the late professor Robert Kerwin and has made a major and unique contribution by writing the Maudsley Prescribing Guidelines[11] for 25 years. Taylor is the de facto editor of this publication and is the only author to be credited on all 13 editions. The Maudsley Prescribing Guidelines have sold over 300,000 copies in thirteen editions and twelve languages. He has also co-written three other books in the Maudsley Prescribing Guidelines series.[12][13][14]

Lectures

Professor Taylor has lectured throughout the world, including tours of New Zealand (2011), Hong Kong (2016), Australia (2019) and Japan (2019). He was a keynote speaker at the 2018 annual meeting of Royal Australian and New Zealand College of Psychiatrists in Auckland and at the Royal College of Psychiatrists annual meeting in London in 2019.[15]

Selected publications
  • South London and Maudsley and Oxleas NHS Trusts Prescribing Guidelines, D Taylor, R Kerwin, C Paton, Taylor and Francis, London, 2005
  • The Maudsley prescribing guidelines. Informa Healthcare, D Taylor, C Paton, S Kapur, London, 2009
  • Atypical antipsychotics and weightgain—a systematic review, DM Taylor, R McAskill, Acta Psychiatrica Scandinavica 101 (6), 416–432, 2000
  • Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014 Mar 19;348:g1888. David Taylor, Anna Sparshatt, Seema Varma, Olubanke Olofinjana
  • Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study, RL Carhart-Harris, M Bolstridge, J Rucker, CMJ Day, D Erritzoe, M Kaelen, The Lancet Psychiatry 3 (7), 619-627 2016.
  • Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019; 6: 538–546. Horowitz MA Taylor D
  • The Maudsley Guidelines for Physical Health Conditions in Psychiatry. 2020. David Taylor, Fiona Gaughran, Toby Pillinger. Wiley Blackwell.

References
  1. Trivedi, Shreshtha. "Clinical leaders 2014". Health Service Journal.
  2. "Society appoints 24 new Fellows". Royal Pharmaceutical Society.
  3. "Professor David Taylor MSc PhD FFRPS FRPharmS". King's College London.
  4. "DRIVING UNDER THE INFLUENCE OF DRUGS" (PDF). Gov.uk.
  5. "Membership". GOV.UK.
  6. "Therapeutic Advances in Psychopharmacology". SAGE Journals.
  7. Bachmann, C. J.; Aagaard, L.; Bernardo, M.; Brandt, L.; Cartabia, M.; Clavenna, A.; Fusté, A. Coma; Furu, K.; Garuoliené, K.; Hoffmann, F.; Hollingworth, S. (2017). "International trends in clozapine use: a study in 17 countries". Acta Psychiatrica Scandinavica. 136 (1): 37–51. doi:10.1111/acps.12742. ISSN 1600-0447.
  8. Taylor, David (August 1997). "Pharmacokinetic interactions involving clozapine". The British Journal of Psychiatry. 171 (2): 109–112. doi:10.1192/bjp.171.2.109. ISSN 0007-1250.
  9. Horowitz, Mark Abie; Taylor, David (June 2019). "Tapering of SSRI treatment to mitigate withdrawal symptoms". The Lancet Psychiatry. 6 (6): 538–546. doi:10.1016/s2215-0366(19)30032-x. ISSN 2215-0366.
  10. Horowitz, Mark Abie; Murray, Robin M.; Taylor, David (2020-08-05). "Tapering Antipsychotic Treatment". JAMA Psychiatry. doi:10.1001/jamapsychiatry.2020.2166.
  11. https://www.psychiatrist.com/JCP/article/Pages/maudsley-prescribing-guidelines-psychiatry-th-ed.aspx
  12. Feetam, Celia (2006). "The Maudsley 2005–2006 Prescribing Guidelines (8th edn). David Taylor, Robert Kerwin & Carol Paton. London: Taylor & Francis, 2005, £19.95 pb, pp. 383. ISBN 1841845000". Psychiatric Bulletin. 30 (11): 437–437. doi:10.1192/pb.30.11.437-a. ISSN 0955-6036.
  13. "The Maudsley: prescribing guidelines (book review)". Pharmaceutical Journal.
  14. Jenkins, James (2016). "The Maudsley Prescribing Guidelines in psychiatry 12th Ed". Journal of Clinical Psychiatry. 77(4): e469.
  15. https://www.rcpsych.ac.uk/events/congress2019/programmev1
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.